{"docid":"VWS-WOO-Spc2-1125422","collapsed":true,"count":1,"unchecked":0,"snapshots_total":3,"versions":[{"archive_id":"folder_import_995_b242bd26689b755c8506f405573ad66a","bestandsnaam":"VWS-WOO-Spc2-1125422.pdf","created_date":"2025-11-13 19:19:50","last_seen":"2025-11-13 19:19:50","from_file":"folder_import","bron":"/volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-Spc2-1125422.pdf","snippet":"1125422    Gespreksverslag regulier overleg VWS-LCG 19-05-21    Notulist:  De volgende agenda wordt doorgenomen;  1.    Evaluatie    2.    Tocilizumab/Budesonide    3.    CCV nieuwe deadline    1.Eval","digest":"896db6990648","dupes":3,"date_to":"2025-11-13 19:19:50","date_from":"2025-10-04 01:21:08","unchecked":false}],"raw":[{"archive_id":"folder_import_995_b242bd26689b755c8506f405573ad66a","bestandsnaam":"VWS-WOO-Spc2-1125422.pdf","created_date":"2025-11-13 19:19:50","last_seen":"2025-11-13 19:19:50","from_file":"folder_import","bron":"/volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-Spc2-1125422.pdf","snippet":"1125422    Gespreksverslag regulier overleg VWS-LCG 19-05-21    Notulist:  De volgende agenda wordt doorgenomen;  1.    Evaluatie    2.    Tocilizumab/Budesonide    3.    CCV nieuwe deadline    1.Eval","digest":"896db6990648"},{"archive_id":"folder_import_995_03de8e4089862f7ddea8f768838e72b5","bestandsnaam":"VWS-WOO-Spc2-1125422.pdf","created_date":"2025-11-13 17:52:42","last_seen":"2025-11-13 17:52:42","from_file":"folder_import","bron":"documenten_files/VWS-WOO-Spc2-1125422.pdf","snippet":"1125422    Gespreksverslag regulier overleg VWS-LCG 19-05-21    Notulist:  De volgende agenda wordt doorgenomen;  1.    Evaluatie    2.    Tocilizumab/Budesonide    3.    CCV nieuwe deadline    1.Eval","digest":"896db6990648"},{"archive_id":"VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip_778","bestandsnaam":"VWS-WOO-Spc2-1125422.pdf","created_date":"2025-10-04 01:21:08","last_seen":"2025-10-04 01:21:08","from_file":"VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip","bron":"/volume3/websites/openrijksoverheid/archieven_files/VWS-WOO-4096451-1081744-d00-1f09d9e8-2505-6ab8-a3e2-a5573eed69c6.zip","snippet":"1125422    Gespreksverslag regulier overleg VWS-LCG 19-05-21    Notulist:  De volgende agenda wordt doorgenomen;  1.    Evaluatie    2.    Tocilizumab/Budesonide    3.    CCV nieuwe deadline    1.Eval","digest":"896db6990648"}],"filename":"190521 Notulen Meeting VWS-LCG.pdf","truncated":false,"elapsed_ms":12}